Prothena Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Prothena şirketinin toplam hissedar öz sermayesi $534.4M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $595.3M ve $60.9M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$519.26m
Eşitlik	US$534.36m
Toplam yükümlülükler	US$60.89m
Toplam varlıklar	US$595.25m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 0Y3M 'nin kısa vadeli varlıkları ( $535.0M ) kısa vadeli yükümlülüklerini ( $46.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: 0Y3M şirketinin kısa vadeli varlıkları ( $535.0M ) uzun vadeli yükümlülüklerini ( $14.5M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 0Y3M borçsuzdur.

Borcun Azaltılması: 0Y3M son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 0Y3M şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: 0Y3M tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Prothena Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Third quarter 2024 earnings released: US$1.10 loss per share (vs US$0.41 profit in 3Q 2023)

Prothena Corporation plc to Report Q3, 2024 Results on Nov 12, 2024

Prothena Corporation plc Announces Appointment of Chad Swanson as Chief Development Officer

Second quarter 2024 earnings released: EPS: US$1.24 (vs US$1.03 loss in 2Q 2023)

Prothena Corporation plc Revises Financial Guidance for the Full Year of 2024

Prothena Corporation plc to Report Q2, 2024 Results on Aug 08, 2024

First quarter 2024 earnings released: US$1.35 loss per share (vs US$0.89 loss in 1Q 2023)

Prothena Corporation plc to Report Q1, 2024 Results on May 08, 2024

Prothena Corporation plc, Annual General Meeting, May 14, 2024

Prothena Appoints David Ford to Newly Created Chief People Officer

Full year 2023 earnings released: US$2.76 loss per share (vs US$2.47 loss in FY 2022)

Prothena Corporation plc has filed a Follow-on Equity Offering in the amount of $250 million.

Prothena Corporation plc Announces Board Changes

Full year 2023 earnings released: US$2.76 loss per share (vs US$2.47 loss in FY 2022)

Prothena Corporation plc Provides Earnings Guidance for the Year 2024

Prothena Corporation plc to Report Q4, 2023 Results on Feb 15, 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: EPS: US$0.41 (vs US$0.97 loss in 3Q 2022)

Prothena Corporation plc to Report Q3, 2023 Results on Nov 02, 2023

Prothena Reportedly Prepares for Potential Sale

Prothena Reportedly Prepares for Potential Sale

Second quarter 2023 earnings released: US$1.03 loss per share (vs US$0.88 loss in 2Q 2022)

Prothena Corporation plc to Report Q2, 2023 Results on Aug 03, 2023

Prothena Corporation plc Presents New Research in the Treatment of Alzheimer's Disease At Alzheimer's Association International Conference®? 2023

Prothena C Corporation plc Announces Phase VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV Al Amyloidosis Treated with Birtamimab

Prothena Corporation plc Appoints Billy Dunn to its Board of Directors

First quarter 2023 earnings released: US$0.89 loss per share (vs US$0.78 loss in 1Q 2022)

Prothena Corporation plc Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$2.47 loss per share (vs US$1.51 profit in FY 2021)

Prothena Corporation plc to Report Q4, 2022 Results on Feb 23, 2023

Prothena Corporation plc Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005

Prothena Corporation plc Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH 2022

Third quarter 2022 earnings released: US$0.97 loss per share (vs US$2.39 profit in 3Q 2021)

Prothena Corporation plc to Report Q3, 2022 Results on Nov 03, 2022

Prothena Corporation plc Appoints Helen S. Kim to its Board of Directors

Second quarter 2022 earnings released: US$0.88 loss per share (vs US$0.62 profit in 2Q 2021)

Prothena Corporation plc Provides Earnings Guidance for the Year 2022

Prothena Corporation plc to Report Q2, 2022 Results on Aug 08, 2022

Prothena Corporation plc(NasdaqGS:PRTA) dropped from Russell Microcap Value Index

Investor sentiment deteriorated over the past week

Prothena Corporation plc Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer's Disease

Prothena Corporation plc, Annual General Meeting, May 17, 2022

Prothena Corporation plc Announces U.S. Food and Drug Administration Clearance of IND for PRX012, A Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Prothena Corporation plc Provides Earnings Guidance for the Year 2022

Prothena Corporation plc to Report Q4, 2021 Results on Feb 17, 2022

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS US$2.39 (vs US$0.77 loss in 3Q 2020)

Forecast to breakeven in 2021

Second quarter 2021 earnings released: EPS US$0.62 (vs US$0.66 loss in 2Q 2020)

Forecast to breakeven in 2021

Forecast to breakeven in 2021

First quarter 2021 earnings released: US$0.91 loss per share (vs US$0.59 loss in 1Q 2020)

Prothena Corporation plc Provides Earnings Guidance for the Year 2021

Revenue beats expectations

Full year 2020 earnings released: US$2.79 loss per share (vs US$1.95 loss in FY 2019)

Prothena Corporation plc Announces Promising New Preclinical and Clinical Data from Its Neurodegenerative Programs Selected for Oral Presentations At AD/PD 2021

Full year 2020 earnings released: US$2.79 loss per share (vs US$1.95 loss in FY 2019)

Revenue beats expectations

Prothena Corporation plc to Report Q4, 2020 Results on Feb 11, 2021

Prothena Corporation plc Announces Confirmatory Phase 3 AFFIRM-AL Study of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin